You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
429 Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to September 2024

AbstractFullPdf
Nov 2021426024
Dec 2021106012
Jan 2022248018
Feb 20225802
Mar 2022190014
Apr 2022120022
May 202266015
Jun 20227405
Jul 20225205
Aug 202274015
Sep 20225407
Oct 202244012
Nov 202246017
Dec 20226405
Jan 202370010
Feb 20236006
Mar 20236003
Apr 20235007
May 20239409
Jun 20233806
Jul 20232408
Aug 20234008
Sep 20232801
Oct 20234404
Nov 20234805
Dec 20238207
Jan 20242605
Feb 20243006
Mar 20243409
Apr 202428011
May 20244603
Jun 202452014
Jul 20243605
Aug 202432014
Sep 202450022
Total25940336